Literature DB >> 12486875

Interactions between opioid and chemokine receptors: heterologous desensitization.

Amber D Steele1, Imre Szabo, Filip Bednar, Thomas J Rogers.   

Abstract

The opioid and chemokine receptors are both members of the seven transmembrane G protein-coupled receptor (GPCR) superfamily. Desensitization is believed to be a major element of the regulation of the function of these receptors, and recent findings suggest that both agonist-dependent (homologous) desensitization and heterologous desensitization can control receptor activity. The cross-desensitization between opioid and chemokine receptors has significant implications for our understanding of both the regulation of leukocyte trafficking, as well as the regulation of chemokine receptor function in inflammatory disease states. We also review findings which suggest that pro-inflammatory chemokine receptor-induced heterologous desensitization of opioid receptors has important implications for the regulation of opioid receptor function in the nervous system.

Mesh:

Substances:

Year:  2002        PMID: 12486875     DOI: 10.1016/s1359-6101(02)00007-2

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  37 in total

Review 1.  Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism.

Authors:  Lindsay Festa; Olimpia Meucci
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

2.  Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.

Authors:  Silke Heinisch; Jonathan Palma; Lynn G Kirby
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

3.  Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

Authors:  Parvathi Ranganathan; Hao Chen; Miranda K Adelman; Samuel F Schluter
Journal:  J Neuroimmunol       Date:  2009-10-30       Impact factor: 3.478

Review 4.  Disruption of neuronal CXCR4 function by opioids: preliminary evidence of ferritin heavy chain as a potential etiological agent in neuroAIDS.

Authors:  Jonathan Pitcher; Saori Shimizu; Silvia Burbassi; Olimpia Meucci
Journal:  J Neuroimmunol       Date:  2010-06-08       Impact factor: 3.478

5.  Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats.

Authors:  Xiaohong Chen; Ellen B Geller; Thomas J Rogers; Martin W Adler
Journal:  Drug Alcohol Depend       Date:  2006-10-17       Impact factor: 4.492

6.  Cross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1.

Authors:  Filip Bednar; Changcheng Song; Giuseppe Bardi; William Cornwell; Thomas J Rogers
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

7.  A role for inflammatory mediators in heterologous desensitization of CysLT1 receptor in human monocytes.

Authors:  Valérie Capra; Maria Rosa Accomazzo; Fabrizio Gardoni; Silvia Barbieri; G Enrico Rovati
Journal:  J Lipid Res       Date:  2009-11-15       Impact factor: 5.922

8.  Glutamate receptor subtypes evidenced by differences in desensitization and dependence on the GLR3.3 and GLR3.4 genes.

Authors:  Nicholas R Stephens; Zhi Qi; Edgar P Spalding
Journal:  Plant Physiol       Date:  2007-12-27       Impact factor: 8.340

9.  The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats.

Authors:  Xiaohong Chen; Ellen B Geller; Thomas J Rogers; Martin W Adler
Journal:  Brain Res       Date:  2007-03-28       Impact factor: 3.252

10.  Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor.

Authors:  Matthew J Finley; Xiaohong Chen; Guiseppe Bardi; Penny Davey; Ellen B Geller; Lily Zhang; Martin W Adler; Thomas J Rogers
Journal:  J Neuroimmunol       Date:  2008-06-03       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.